At ViVE 2024 in Los Angeles, COTA’s Chief Medical Officer, C.K. Wang, MD will take part in a discussion session called “Data That’s Getting Personal”.
Before raw, real-world data (RWD) can be transformed into actionable insights, it has to go through a number of different processes, from aggregation and abstraction to standardization and careful curation.
A huge number of new breakthroughs in drug development, treatment guidelines, and decision support technologies occur every day to treat blood cancers.
Large language models (LLMs) are the foundation of highly hyped generative AI tools like Chat-GPT and Google Bard.
To ring in the new year, we asked COTA’s leadership team about their top predictions for 2024 in the oncology, real-world data, and life sciences spaces.
In our blog series with Deloitte, we have written extensively about the benefits of using Real World Data to enhance clinical trials and accelerate research into new therapies for a variety of conditions.
This collaboration enables Aetion and COTA to meet the needs of researchers requiring high-quality, clinically rich oncology data, for both liquid and solid tumor types.
Life sciences researchers and oncologists are learning more about cancer pathogenesis and treatment every day, largely thanks to explosive innovation in the world of biomarkers.
This blog series talks extensively about the benefits of using real-world data (RWD) to enhance clinical trials and accelerate research into new therapies for a variety of different conditions. Now it’s time to take a closer look at the details.
Today, COTA is introducing COTA Connect: a powerful new capability to link data with a variety of different supplemental data sources, including linking COTA’s robust real-world clinical data to claims, imaging, socioeconomic data, and more.